Management of Lower-Risk Myelodysplastic Syndromes
The management of myelodysplastic syndromes is complicated by the generally advanced age of the patients, the non-hematologic comorbidities seen in this cohort, and the relative inability of older patients to tolerate certain intensive forms of therapy. There are limited treatment options for patients with disease progression, especially for those with disease refractory to hypomethylating agents.
NCCN Guidelines® Insights - Myelodysplastic Syndromes, Version 3.2022
These NCCN Guidelines Insights focus on some of the updates for the 2022 version of the NCCN Guidelines, which include treatment recommendations both for lower-risk and higher-risk MDS, emerging therapies, supportive care recommendations, and genetic familial high-risk assessment for hereditary myeloid malignancy predisposition syndromes.
Interactive Online Case Studies: Leukemia, Myelodysplastic Syndromes, and Myeloproliferative Disorders - Case 2
Advances in Personalized Therapeutic Approaches in Myelodysplastic Syndromes

Patients who do not respond to current therapies for myelodysplastic syndromes (MDS) have limited options. Advances in molecular testing suggest the potential for improved risk stratification and prognostication for patients with MDS.

Management of Myelodysplastic Syndromes

This information was originally presented at the NCCN 10th Annual Congress: Hematologic Malignancies™ held in San Francisco, California.

NCCN Guidelines® Insights - Myelodysplastic Syndromes, Version 2.2015

The NCCN Guidelines for Myelodysplastic Syndromes (MDS) comprise a heterogeneous group of myeloid disorders with a highly variable disease course that depends largely on risk factors. Risk evaluation is therefore a critical component of decision-making in the treatment of MDS.

Role of Molecular Advances in the Classification and Prognosis of MDS

This information was originally presented on September 20, 2014, at the NCCN 9th Annual Congress: Hematologic Malignancies™ held in New York, New York.

An Unusual Presentation of Chronic Myelogenous Leukemia: A Review of Isolated Central Nervous System Relapse

Many effective therapeutic options are available for patients with chronic myelogenous leukemia (CML). Imatinib, a first-generation tyrosine kinase inhibitor (TKI), is one of several options for patients who present with CML, whether in chronic phase, accelerated phase, or blast crisis.

The Multifaceted Nature of Myelodysplastic Syndromes: Clinical, Molecular, and Biological Prognostic Features

The myelodysplastic syndromes (MDS) consist of a heterogeneous spectrum of myeloid clonal hemopathies. The Revised International Prognostic Scoring System (IPSS-R) provides a recently refined method for clinically evaluating the prognosis of patients with MDS.

Personalization of Therapy for MDS: The Role of Biology, Risk Stratification, and Evolving Therapies

This information was originally presented on September 14, 2012, at the NCCN 7th Annual Congress: Hematologic Malignancies™ held in New York, New York.

Pages

Subscribe to RSS - Myelodysplastic Syndrome